Tryglicerides HyperTrig at switch No HyperTrig at switch 224 (183; 316) 114 (87; 129) 112 (89; 187) 102 (82; 136) -99 (-163; - 55) 2 (-20; 27) 170 (158; 239) 108 (64; 118) 142 (111; 191) 104 (74; 149) -39 (-75; - 15) -2 (-19; 72) 0.204 0.927 Cholesterol LDL Hyperchol LDL at switch No Hypercol LDL at switch 143 (139; 160) 89 (73; 113) 116 (110; 127) 78 (66; 95) -28 (-32; - 8) -2 (-14; -9) 170 (15; 180) 93 (78; 106) 142 (114; 179) 83 (70; 101) 27 (-37; 34) -4 (-5; 5) 0.243 0.410 Creatinine Crea >=1.2 at switch Crea <1.2 at switch 1.38 (1.30; 1.68) 0.82 (0.71; 0.98) 1.26 (1.14; 1.55) 0.87 (0.72; 0.99) -0.13 (-0.14; - 0,09) 0.03 (-0.03; 0.07) 1.30 (1.25; 1.35) 0.92 (0.81; 1.03) 1.01 (1.12; 0.90) 0.78 (0.69; 0.89) -0.29 (-0.35; - 0.23) -0.12 (-0.21; - 0.03) 0.036 0.949 Conclusions: DOR-based regimen confirmed favourable lipid profile, especially when combined with TDF/FTC. The association with TAF/FTC seemed to be safer in PLWH with baseline KI. The side effects prevalence was not negligible, deserving further investigation. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 135
RkJQdWJsaXNoZXIy Mzc2ODc=